Global Kidney Cancer Drugs Market, by Therapy (Targeted Therapy, Immunotherapy and Chemotherapy), by Pharmacological Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, Antimetabolites and Others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 5.83 Billion in 2022 and is expected to exhibit a CAGR of 6.4% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing launches of new drugs for treatment of kidney cancer at lower prices is expected to drive the global kidney cancer drug market over the forecast period. For instance, in February 2021, Glenmark Pharmaceuticals, a pharmaceutical company launched a generic kidney cancer treatment drug 'Sunitinib oral capsules' in India priced 96 per cent lower compared to the innovator brand. Sunitinib is also approved by the U.S. Food and Drug Administration (USFDA). The drug is launched at a Maximum Retail Price that is approximately 96 per cent lower than the MRP (maximum retail price) compared to the innovator brand which are priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5 mg) per month.
Global Kidney Cancer Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the global kidney cancer drugs market, owing to decrease in the diagnosis of the kidney cancer and the supply of the drug used to treat renal carcinoma and kidney cancer. For instance, in August 2020, according to the data published by the National Center for Biotechnology Information, the National Health System in U.K. (NHS England) had recommended that at the peak of the pandemic, hospitals should prioritize patients who require an urgent operation within the subsequent 24–72 hours. Secondly, diagnosis was delayed as screening programs and diagnostic services had been decreased or suspended in several countries, and patients, wary of exposing themselves to the risk of infection, had been more reluctant to present to healthcare services. Several clinical trials were suspended, which had reduced current therapy options for patients who might have participated, which has endangered longer-term therapy development.
Global Kidney Cancer Drugs Market: Key Developments
In June 2022, according to the Clinical Hospital of the Faculty of Medicine of Ribeirão Preto, Clinical Trial Organization adjuvant everolimus improves recurrence-free survival (RFS) in patients with fully resected renal cell carcinoma (RCC) who have a very high risk of disease recurrence, a phase 3 trial suggests. Adjuvant Everolimus appears beneficial in very high-risk kidney cancer according to the phase 3 trial.
On June 27 2022, researchers at Karolinska Institute in Europe have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell. When the researchers increased the mitochondrial content with an inhibitor, the cancer cells responded to the treatment.
Browse 25 Market Data Tables and 29 Figures spread through 173 Pages and in-depth TOC on “Global Kidney Cancer Drugs Market”- Forecast to 2030, Global Kidney Cancer Drugs Market, by Therapy (Targeted Therapy, Immunotherapy and Chemotherapy), by Pharmacological Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, Antimetabolites and Others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/kidney-cancer-drugs-market-2399
Key Takeaways of the Global Kidney Cancer Drugs Market:
- Global kidney cancer drugs market is expected to exhibit a CAGR of 6.4% during the forecast period due to increasing research and development activities by key players in market. For instance, in August 2020, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd, a pharmaceutical company, carried out randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.
- Among pharmacologic class, angiogenesis inhibitors segment accounted for the largest share in 2022. Angiogenesis inhibitor drugs play an important role in restricting growth of cancer cells. Angiogenesis inhibitors block nutrients and oxygen supply to tumor in the kidney. Some of the angiogenesis inhibitor drugs used in kidney cancer treatment include Axitinib (Inlyta), Bevacizumab (Avastin), and Cabozantinib (Cometriq), among others.
- Among regions, North America is estimated to account for the largest market share in the global kidney cancer drugs market over the forecast period, owing to increasing prevalence of the renal cell carcinoma. For instance, in February 2022, according to American Society of Clinical Oncology (ASCO) in the U.S., kidney cancer is the sixth most common cancer for men. It is the ninth most common cancer for women. The average age at diagnosis for people with kidney cancer is 64, and most people are diagnosed between the ages of 65 and 74. The number of new kidney cancers in the U.S. has been increasing for several decades, although that increase has slowed in recent years. Between 2009 and 2018, rates rose by around 1% each year. Some of the increase has been due to an increase in the overall use of imaging tests. Imaging tests can find small kidney tumors unexpectedly when the tests are done for another reason unrelated to the cancer.
- Major players operating in the global kidney cancer drugs market include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
